Tranexamic acid use in the setting of ACE inhibitor induced angioedema

Tranexamic add (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein. It has been utilized in angiotensin converting enzyme (ACE) inhibitor-induced angioedema (ACEi-AE) in small case reports and series however overall data is limited. This report describes a patient who historically received TXA for ACEi-AE and represented with ACEi-AE after an accidental exposure and was successfully treated with TXA again. This case suggests TXA may be a safe and effective treatment option for ACEi-AE. (C) 2022 Elsevier Inc. All rights reserved.

Automated summary

Tranexamic acid is a potentially safe and effective treatment option for angiotensin converting enzyme inhibitor-induced angioedema, according to this case report. Previous small case reports have demonstrated the efficacy of tranexamic acid in treating this condition, and this report provides further evidence of its effectiveness.